Key Highlights
• Four AI-Identified Molecules Tested: NorthStrive's AI-driven collaboration with Yuva Biosciences identified four small molecules that improved ANT1 expression in primary skeletal muscle cells.
• Peak ANT1 Expression Improvement of 50%: The four molecules demonstrated peak responses of 50% improvement in ANT1 expression levels in primary skeletal muscle cell assays.
• Advancing to Mature Skeletal Muscle Models: The program is moving toward confirmatory testing in more mature skeletal muscle models as the next scientific validation step before clinical development.
PMGC Holdings (NASDAQ: ELAB) issued a formal release detailing Phase 3 results from NorthStrive's AI-driven collaboration with Yuva Biosciences, revealing that four small molecules identified through artificial intelligence improved ANT1 expression levels in primary skeletal muscle cells with peak responses reaching 50%, as the company advances its muscle metabolism program toward the next stage of scientific validation.
ANT1, or Adenine Nucleotide Translocator 1, is a mitochondrial membrane protein that plays a critical role in the transport of ATP out of and ADP into mitochondria within skeletal muscle cells — a fundamental step in cellular energy production and muscle function. Impaired ANT1 expression or function has been linked to mitochondrial myopathy, muscle weakness disorders, and age-related muscle loss, making it a biologically meaningful target for potential therapeutic intervention.
The program's use of artificial intelligence to identify the four candidate molecules represents the drug discovery phase of the development pipeline. AI-assisted small molecule screening allows researchers to evaluate vastly larger chemical libraries than traditional high-throughput screening methods, with machine learning models trained to predict biological activity based on molecular structure and target characteristics.
The 50% peak improvement in ANT1 expression observed in primary skeletal muscle cells provides an early proof-of-concept signal that the AI-identified molecules are engaging their intended biological target and producing a measurable functional response. However, primary cell assays represent an early-stage experimental system, and reproducibility of these findings in more physiologically complex models is the critical next validation requirement.
Advancement toward confirmatory testing in more mature skeletal muscle models — such as differentiated myotube cultures or ex vivo muscle tissue preparations — will determine whether the biological activity observed in primary cells translates to more physiologically relevant experimental systems, the key scientific question that will inform whether these compounds have a viable path toward formal clinical development.
()






Please wait processing your request...